Nishinomiya, Japan

Tominori Morita


Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Nishinomiya, JP (1980 - 1992)
  • Nara-ken, JP (1997)

Company Filing History:


Years Active: 1980-1997

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Tominori Morita: Innovator in Pharmaceutical Chemistry

Introduction

Tominori Morita is a distinguished inventor based in Nishinomiya, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 5 patents. His work focuses on developing innovative compounds that address critical health issues.

Latest Patents

Among his latest patents is a 1,4-benzoxazine derivative and pharmaceutical compositions containing it. This compound is designed to be a medicament for preventing or treating disorders induced by intracellular acidosis during myocardial ischemia. Such disorders include cardiac dysfunction, myocardial necrosis, arrhythmia, and reperfusion injury, which are commonly observed in ischemic heart diseases like myocardial infarction and angina pectoris. Another notable patent involves novel cyanoguanidine derivatives, which exhibit K+ channel opening activity. These compounds are useful as hypotensive agents and coronary vasodilators.

Career Highlights

Tominori Morita is currently associated with Kanebo, Limited, where he continues to innovate in the pharmaceutical sector. His research and development efforts have led to advancements that hold promise for improving patient outcomes in cardiovascular health.

Collaborations

He has collaborated with notable colleagues, including Goro Tsukamoto and Koichiro Yoshino, to further enhance the impact of his research.

Conclusion

Tominori Morita's contributions to pharmaceutical chemistry exemplify the importance of innovation in addressing health challenges. His patents reflect a commitment to developing effective treatments for serious medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…